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Abstract: Cervical cancer and its precursor intra-epithelial lesions are linked to infection by a subset of so-called “high-
risk” human papillomavirus types, which are estimated to infect nearly four hundred million women worldwide. Two 
prophylactic vaccines have been commercialized recently targeting HPV16 and 18, the most prevalent viral types found in 
cervical cancer, which operate through induction of capsid-specific neutralizing antibodies. However, in patients with 
persistent infection these vaccines have not been found to protect against progression to neoplasia. Attempts are being 
made to develop therapeutic vaccines targeting nonstructural early viral proteins. Among these, E6 and E7 are the 
preferred targets, since they are essential for induction and maintenance of the malignant phenotype and are constitutively 
expressed by the transformed epithelial cells. Here are reviewed the most relevant potential vaccines based on HPV early 
antigens that have shown efficacy in preclinical models and that are being tested in clinical studies, which should 
determine their therapeutic capacity for eradicating HPV-induced premalignant and malignant lesions and cure cervical 
cancer. 
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INTRODUCTION 
  Carcinoma of the uterine cervix, or cervical cancer 
(CxCa), is the second most frequent cause of death by 
neoplasia in women worldwide with half a million new cases 
and nearly 300,000 deaths every year [1, 2]. About 60,000 
new cases of invasive CxCa and 30,000 deaths are estimated 
yearly in European countries (including the Russian 
Federation) [3]. The American Cancer Society estimates that 
in 2008, nearly 11,000 women will be diagnosed with 
cervical cancer in the United States, and approximately 
4,500 deaths are expected [4, 5]. Before the vaccine era it 
was estimated that towards the middle of this century the 
global incidence of CxCa might be one million cases per 
year with an approximate average mortality of 40% [6]. It is 
still not known whether the two prophylactic vaccines 
targeting HPV16 and 18, the most prevalent viral types 
found in cervical cancer, will help reduce CxCa morbidity 
and mortality since their efficacy in the long term has not 
been assessed yet [7]. 
  HPV belongs to a genus in the Papovavirus family [8] 
consisting of non-enveloped DNA viruses (Fig. 1) 
characterized by a strict epithelial tropism and their capacity 
to induce epidermal proliferation. A subset of these viruses, 
known as high-risk HPVs (HR-HPVs), has been linked to 
CxCa through epidemiological and experimental studies [9]. 
These have been limited by the strict species specificity of 
HPVs and their incapacity to propagate in vitro by 
conventional methods, although the latter was overcome   
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recently by transfection of codon-optimized HPV capsid 
genes [10]. The oncogenic ability of HR-HPV has been 
shown by molecular studies in vitro [11], and in transgenic 
mice [12, 13]. The HPV genome is a circular DNA molecule 
of about 8,000 base pairs (Fig. 2, right), which contains a 
long control region and up to eight open reading frames 
encoding non-structural and capsid proteins (Table 1). E1, 
E2 and E4 are indispensable for viral replication, regulation 
of transcription and genome amplification, respectively. E5, 
E6 and E7 have transforming functions such as activation of 
the epidermal growth factor receptor and the PI3/Akt 
pathway, promotion of p53 degradation and inactivation the 
retinoblastoma protein (pRb), respectively (see [14] for a 
review). 
  The life cycle of HR-HPV is tightly linked to 
differentiation of the cervical epithelium beginning with the 
infection of basal cells most likely through negligible lesions 
(Fig. 2, left) [15]. In the infected basal cells the viral genome 
persists episomally and is transcribed into a bicistronic 
message that encodes the early E6 and E7 proteins, which 
promote cellular proliferation. As these cells migrate towards 
upper epithelial layers and differentiate, expression of E6 
and E7 is switched off and new transcripts are released 
encoding proteins required for viral genome amplification, 
most notably E4. Finally, a number of the E4-expressing 
cells synthesize the capsid proteins L1 and L2, required for 
assembly of infectious viral particles. In some cells, 
however, productive infection is aborted and the viral DNA 
may integrate into the host genome from where the E6 and 
E7 genes are constitutively transcribed. Continuous 
expression of E6 and E7 proteins causes cellular 
transformation leading to increasingly severe epithelial 
lesions known as cervical intraepithelial neoplasia (CIN), 
which may eventually progress to invasive cervical cancer. 68    The Open Virology Journal, 2009, Volume 3  Angel Cid-Arregui 
 
Fig. (1). Computer generated image of a virus-like particle of HPV type 16 [125] (Courtesy of Dr. Jean_Yves Sgro, http://www.virology. 
wisc.edu/virusworld/viruslist.php?virus=hpv). 
 
Fig. (2). Organization of the HPV genome and sequence of viral gene expression along keratinocyte differentiation in the cervical stratified 
epithelium. Initially, HR-HPVs infect basal keratinocytes. The viral genome resides in the nuclei of basal cells as a low-copy plasmid, which 
expresses its early genes at very low levels. The E6 and E7 proteins cause up-regulation of cellular proteins necessary for entry into S-phase. 
As the infected basal cells migrate towards the epithelial surface, the late promoter becomes activated and drives expression of proteins 
necessary for viral genome amplification (E4). Only a subset of E4(+) cells express the L1 major and minor L2 capsid proteins, allowing 
packaging of viral genome into infectious particles. During cancer progression, the normal papillomavirus life cycle is disrupted and virus 
particles are not produced. This represents an abortive infection for the virus. In high-grade cervical neoplasia, cells expressing the viral E7 
protein can be found close to the epithelial surface. Expression of the E4 protein and the onset of viral genome amplification do not occur. 
(Slightly modified from J Doorbar, with permission) [15]. HPV Vaccines  The Open Virology Journal, 2009, Volume 3    69 
Table 1.  Proteinsencoded by HR-HPV and Known Functions 
for Them 
 
Gene Function 
E1 Initiation  of  DNA replication 
E2  Transcriptional regulation/DNA replication 
E3 ? 
E4 Cytoskeleton  disruption? 
E5  Transforming protein, interacts with growth factor receptors 
E6  Transforming protein, binds to p53, leading to degradation 
E7  Transforming protein, binds to pRB 
E8 ? 
L1 Major  capsid  protein 
L2 Minor  capsid  protein 
 
  More than 100 HPV types have been identified to date, of 
which about 30 have genital tropism. These have been divided 
into two groups according to their prevalence in genital tumors: 
1) “Low-risk” HPV, associated benign lesions such as 
condiloma, the most frequent types being HPV 6 and 11, but 
including also the types 40, 42-44, 54, 61, 70, 72 and 81; and 2) 
“High-risk” HPV, which are involved in the etiology of cervical 
cancer, including HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 68, 73, 82, as demonstrated by epidemiological studies 
[16, 17]. HPV16 is the most prevalent HPV type, found in 
approximately 50% of CIN and CxCa cases, followed by 
HPV18, 31 and 45 which account for an additional 30%. 
Infection by high-risk HPV is very frequent among sexually 
active women, with an incidence of 15-40% [18]. It has been 
estimated that by the age of 50 years at least 80% of women 
have encountered a high-risk HPV infection at some point of 
their lives, which makes HPV the most common sexually 
transmitted agent. Follow-up studies have shown that in 90% of 
cases HPV infection is cleared [4]. However, in the remainder 
10% the infection persists more than two years and these 
women are at high risk of developing CxCa [1, 19, 20]. 
  The incidence of CxCa in developed countries decreased 
significantly since the introduction of cytological screening 
programs. Unfortunately, developing countries cannot afford 
such programs. The recent commercialization of prophylactic 
HPV vaccines has opened new hopes for the eradication of at 
least part of the HPV-associated diseases. These vaccines are 
based on the major capsid proteins (L1) of the most prevalent 
HPV types. However, women already infected by these HPV 
types cannot benefit from such vaccines and are at risk of 
developing CxCa. Given the high mortality rate of invasive 
CxCa, further investigation to develop immunotherapeutic 
approaches is needed. Here we review the most relevant aspects 
of the immune response to HPV in CIN and CxCa and the 
clinical studies applying current therapeutic vaccine strategies 
against neoplasia associatedwith HPV. 
INNATE AND ACQUIRED IMMUNE RESPONSES TO 
HPV 
  Persistence of HPV infection is the consequence of the 
failure of the host immune system to eliminate the infected 
cells. This may be due to the fact that HPV propagate 
without causing neither lysis of keratinocytes nor viremia. 
Besides, a local immunosuppressive tendency associates 
with HPV lesions and surrounding tissues, so that no 
inflammatory response is observed [21]. This has been 
attributed to the capacity of the viral proteins, in particular 
E7, to induce tolerance [22, 23]. According to this, dendritic 
cells (DCs) infiltrating the epithelial layers (Langerhans 
cells) loaded with E7 protein from apoptotic tumor cells 
would not be able to mature and would induce tolerance 
rather than cytotoxic responses. Moreover, continuous 
expression of E7 in CIN lesions during years would favor its 
presentation as autoantigen. Further, the low expression level 
of E7, in part due to the biased codon usage of the viral 
genome [24] might facilitate tolerance to this protein. 
  A number of observations indicate that HPVs have 
evolved mechanisms to evade the host immune system: 1) 
E7 of HPV 16 has a high degree of homology with several 
human proteins [25], which might facilitate recognition as 
self. 2) E6 and E7 downregulate expression of interferon-
responsive genes in infected keratinocytes [26]. HPV 16 E7 
abrogates the antiviral effects of interferon-alpha (IFN-) 
[27]. Further, E7 interacts with the interferon regulatory 
factor IRF-1 and inhibits the IRF-1-mediated activation of 
the IFN- promoter [28]. E6 and E7 inhibit IL-18-induced 
IFN- in natural killer (NK) cells [29]. 3) Extracellular E7 
protein inhibits T cell responses [30]. 4) E6 reduces 
expression of IL-18 CD8+ [31]. 5) E5 inhibits the 
acidification of endosomes in keratinocytes and may 
interfere with proper antigen presentation [32]. 6) HLA 
expression is altered in cervical neoplasia [33, 34] and this 
may be coupled with defectsin antigen processing. For 
instance, reduced expression of HLA and the transporter 
proteins TAP1 and TAP2 has been described in cervical 
carcinomas [35]. 7) NKG2D-expressing NK and T cells are 
diminished in CxCa patients, who also have increased serum 
levels of soluble MICA (major histocompatibility complex 
class I-related chain A), a ligand of the NKG2D activating 
receptor [36]. 8) Langerhans cells are not activated by HPV 
capsids devoid of genetic material, the so-called virus-like 
particles (VLPs) [37]. 9) Expression of the chemokine 
CCL20, which stimulates infiltration of immature LC in the 
squamous epithelium of the cervix, is altered in HPV-
transformed keratinocytes and could be restored by silencing 
HPV16 E6 and E7 expression by RNA interference [38]. 10) 
Experimental work with transgenic mice has shown that 
expression of HPV 16 E7 under control of the keratin 14 
promoter in the basal cells of the epidermis causes tolerance 
[39]. 
  In spite of the ability of HPV to escape immunosurveil-
lance, HPV infection frequently evokes discrete humoral and 
cellular immune responses [40]. Serological studies based on 
VLPs indicate that in 50% of cases the infection with HPV 
causes a humoral response (IgG) against specific antigenic 
regions (conformational epitopes) of the major capsid 
protein (L1), which correlates with the presence of viral 
DNA in the cervical smear [41]. In the remaining 50% the 
infection disappears leaving behind no detectable antibody 
response. Neutralizing antibodies are found during 
regression of lesions induced by HPV. Further, an antibody 
response against E7 is observed in a high percentage of CIN 
and CxCa cases [42, 43]. 70    The Open Virology Journal, 2009, Volume 3  Angel Cid-Arregui 
 
Fig. (3). Schematic representation of the cellular immune responses to keratinocytes infected by HR-HPVs in pre-cancer and cancer lesions 
of the uterine cervix. A, CIN I and II pre-cancer lesions usually regress spontaneously as result of effective innate and adaptive cytotoxic 
responses. Intraepithelial NK cells become activated by ligands of the NKG2D receptor (1), such as the MHC class I-related molecules A 
and B (MICA and MICB), expressed on the surface of HPV-infected cells, and release the contents of cytolytic granules (2) on the target 
cell. LCs are intraepithelial professional presenting cells, which take up viral antigens (3) released by apoptotic HPV-infected cells, and 
subsequently present viral epitopes (4) to CD4+ (5) and CD8+ T cells (6), which become activated. Upon recognition of HPV antigens 
presented by MHC class I molecules on the surface of HPV-infected cells (7), activated CD8+ T cells also release cytolytic granules (8). 
These granules contain serine proteases called granzymes, which induce programmed cell death in the target cells. Activated CD4
+ T cells 
secrete cytokines that stimulate cytolytic CD8
+ T cells (9). Box 1 summarizes the conditions that allow recognition and eradication of HPV-
infected cells by the immune cells. B, Advanced cervical CIN III pre-cancer and cancer lesions progress while the effectors of cellular 
immunity remain passive or unable to eliminate the HPV-infected/transformed cells. LCs loaded with HPV antigens (1) released by HPV-
infected cells are unable to mature and cannot present antigen to and activate CD4
+ and CD8
+ T cells. Instead, CD4
+FoxP3
+ regulatory T 
cells infiltrate the lesion and down-regulate effector T lymphocytes. Further, NKG2D-ligands on the surface of infected cells undergo 
cleavage and their ectodomains are released (2) as soluble molecules that bind NKG2D on NK cells (3), which thereby become inactive (4). 
In addition, antigen presentation is altered (5). The mechanisms used by HPV to evade immunosurveillance are listed in Box 2. HPV Vaccines  The Open Virology Journal, 2009, Volume 3    71 
  Nevertheless, a number of observations indicate that 
cellular responses against HPV are relevant for eradication 
of established infection: 1) humoral immunodeficiency does 
not predispose to the development of precancerous lesions 
associated with HPV infection [44]. 2) Patients with reduced 
CD4+ T cell function, such as transplanted patients and those 
infected by the HIV, present a higher prevalence of infection 
by HPV and associated CIN lesions. 3) Spontaneous 
regression of CIN lesions is accompanied by a delayed 
hypersensitivity response mediated by CD4+ T cells 
infiltrating the infected epithelium. 4) Cervical tumors 
contain functionally altered DCs [45]. 5) Immunostimulatory 
signals mediated by cytokines are disabled in these tumors 
[46]. 6) In patients with CIN persistently infected by HPV16 
there is an increase in the frequency of CD4
+CD25
hi 
regulatory T cells [47], and the lesions are highly infiltrated 
with CD4
+FoxP3
+ T cells, which are normally absent in the 
cervical epithelium [48]. This suggests that at least part of 
the lymphocytes infiltrating the HPV neoplasia can act 
suppressing anti-tumor immune responses. 7) AIN and VIN 
patients treated with Imiquimod, an agent that stimulates 
TLR-7 on APC and induces Th1 cell-mediated immune 
responses [49], showed specific CD4+ T cell responses to 
HPV 16 correlating with remission of lesions [50-52]. 
  A significant conclusion of the above observations is that 
studies testing the therapeutic capability of new candidate 
vaccines should include a careful examination of the 
patients’ immune system before and after vaccination. While 
humoral immunity generates neutralizing antibodies that 
protect against initial infection, cell-mediated immunity is 
indispensable to eradicate persistent HPV infection and stop 
tumor progression. Further, immunotherapy strategies should 
include effective in situ modulation of the CD4
+ regulatory T 
cell activity, which might require the use of adjuvants that 
generate a convenient cytokine environment at the lesion 
site. Fig. (4) summarizes the interplay between cellular 
effectors of the immune system and HPV-infected cells, 
which might lead to HPV clearance and regression of 
neoplastic lesions in most cases of CIN I and CIN II or to 
tolerance and cancer progression in advanced CIN III. 
 
Fig. (4). An imbalance in the interaction between viral and host factors may lead to clearance of infection and regression of lesions caused by 
HR-HPV or rather to progression to invasive cancer. Most CIN I and CIN II lesions (left side) regress spontaneously. The viral genome 
remains episomal in the infected keratinocytes and viral load is low as is the expression of viral proteins. Under these conditions, the cells 
can differentiate, which allows expression of capsid proteins and virus assembly and release. Antigen processing and MHC class I expression 
remain unaltered. Released viral particles are endocytosed, processed and presented by LCs triggering strong T cell responses. NK cells 
become activated through the NKG2D receptor upon binding to MICA/B expressed on the surface of the infected keratinocytes. In contrast, 
the vast majority of CIN III lesions progress to cancer as result of persistence of viral infection, which leads to integration of the viral DNA 
into the host genome and enhanced viral gene expression. The E6 and E7 viral products interfere with keratinocyte differentiation, and 
antigen presentation. MICA/B molecules undergo shedding by proteases released by the transformed cells and the soluble MICA/B-derived 
polypeptides cause a reduction in the number of NKG2D
+ NK and T cells. Some risk factors such as sexual promiscuity, steroid hormones 
(contraceptives) and smoking may cooperate with the virus by increasing the viral load, enhancing gene expression and the rate of 
mutagenesis, respectively. 72    The Open Virology Journal, 2009, Volume 3  Angel Cid-Arregui 
Tumor-Specific Antigens in HPV Precancerous Lesions 
and Tumors 
  In acute infection by high risk HPVs the expression of E6 
and E7 viral genes takes place in the basal layer of the 
cervical epithelium where they induce up-regulation of 
cellular proteins that control the cell cycle (Fig. 2). As the 
infected cells differentiate and migrate to the surface the 
viral late promoter becomes activated and drives expression 
of proteins involved in amplification of the viral genome, the 
most abundant being E4 [53]. A subset of these cells 
expresses also the L1 and L2 capsid proteins, which 
assemble with the viral genome to form new infectious viral 
particles. 
  During progression towards cervical cancer, the HPV life 
cycle is disrupted and viral particles are not produced [53]. 
Thus, in high-grade cervical dysplasia, expression of E4 and 
viral genome amplification do not occur. Instead, E6 and E7 
expression takes place in upper epithelial layers, where these 
proteins interfere with the regulation of the cell cycle and the 
formation of the mitotic spindle [54] and leads to histologic 
aberrations such as anisonucleosis and hyperchromasia. E6 
and E7 are found constitutively expressed in CxCa as well as 
derived cell lines, such as HeLa (HPV18), SiHa and CaSki 
(HPV16) [9] and therefore, represent tumor-specific antigens 
(TSAs). Both E6 and E7 from HPV16 and 18 contain 
epitopes that are presented by HLA-A2 molecules of the 
MHC class I [55]. Peptides carrying MHC class I restricted 
epitopes from those proteins have been shown to stimulate 
cellular immunity in both animal models and humans [55, 
56]. 
  Besides HPV proteins there are endogenous proteins 
expressed abnormally in precancerous and cancerous 
cervical lesions. Molecular analysis of dysplastic cells found 
in CIN and CxCa lesions has shown a correlation between 
the lesion grade and the expression of HPV E7 with high 
levels of p16
ink4a  [57-59]. This protein is an inhibitor of 
cyclin-dependent kinases that plays a crucial role in the 
regulation of the cell cycle. The expression of p16
ink4a is 
tightly regulated in normal cells, which produce very low 
amounts of this protein that are undetectable by 
immunohistochemical methods. Along with the transdiffer-
entiation process during HPV-induced squamous metaplasia, 
the expression of p16
ink4a is already enhanced in early lesions 
[60], and continues progressively rising to the high levels 
detectable in cells from CIN III and CxCa lesions. Such 
phenomenon results from the transforming activity of E7 
encoded by HR-HPVs, which by inactivating pRb interferes 
with the negative feedback that this protein normally exerts 
on transcription of the p16
ink4a gene. Therefore, p16
ink4a is not 
only an indicator of the oncogenic activity of HR-HPVs but 
also represents a tumor-associated antigen, and hence a 
possible target for immunotherapy. 
Therapeutic HPV Vaccines 
  Although prophylactic vaccines are effective in 
preventing HPV16 and 18 precancerous lesions, and even 
induce cellular immunity to L1, recent clinical studies 
indicate that they have no therapeutic effects [61, 62]. 
Therefore, women already infected with oncogenic HPVs are 
at risk of developing cancer. This warrants further   
 
development of therapeutic vaccines aimed to induce cellular 
immune responses against HPV early antigens such as E6 
and E7, which unlike capsid antigens are constitutively 
expressed in HPV precancerous lesions and tumors. These 
proteins contain antigenic regions that are presented by 
HLA-A2 molecules and have been shown to be 
immunogenic in mouse and humans [63]. Immune responses 
involved in eradication of tumor cells are essentially 
mediated by CD8+ T cells. However, an effective and 
sustained activity of CD8+ T cells requires the collaboration 
of CD4+ helper T cells (Fig. 3). This section describes the 
most relevant clinical studies carried out with therapeutic 
vaccine candidates developed to dateand their reported 
results (Table 2). 
Peptide Vaccines 
  Peptide vaccines are simple, well tolerated and easy to 
produce. The low cost associated with good manufacturing 
production (GMP) of peptide-based vaccines led many 
investigators in the past to initiate clinical studies with 
peptides harboring HLA-A2 epitopes from the E6 and E7 
proteins. A phase I clinical study by Steller et al. [64] 
explored the efficacy of an E7-derived lipopeptide (HPV 16 
E7
86-93) with affinity for HLA-A*0201 molecules, linked to 
then non-specific pan-HLA DR peptide PADRE, which 
carries a helper T cell epítope [65, 66]. Twelve patients with 
refractory cervical or vaginal cancer were selected, who 
received four s.c. doses of the vaccine at three week 
intervals. E7
86-93-specific CLT responses, detected by IFN- 
release assay, were observed in 5 patients after two doses 
and in 2 patients after all four immunizations. Nevertheless, 
no clinical responses were observed in these patients. In a 
different clinical study of phase I/II two HPV 16 peptides 
E7
11-20 and E7
86-93 with high HLA-A*0201 binding capacity 
were utilized emulsified in incomplete Freund’s adjuvant 
(IFA) in combination with the PADRE helper peptide. A 
total of 19 HLA-A*0201+ patients were divided into three 
groups receiving escalating doses of peptide (100, 300 or 
1000 g) s.c., four times at three-week intervals [67]. After 
one-year follow-up two patients showed disease stabilization 
and two others underwent tumor regression after subsequent 
chemotherapy treatment, the rest suffered progressive 
disease. Analysis of PBMCs showed that vaccination did not 
induce E7 peptide-specific CTL in any of these patients and 
that part of the patients had a reduced number of 
lymphocytes, suggesting that the advanced disease in these 
patients caused immunocompromise. 
  A similar vaccine was tested in a phase I study on 18 HLA-
A2 patients with high-grade intraepithelial neoplasia of cervix 
or vulva positive for HPV16 [68]. The patients were vaccinated 
with the E7
12-20 peptide in IFA and the E7
86-93 peptide linked to 
the PADRE helper peptide and a covalently coupled lipid. The 
vaccine was administered in four doses at three-week intervals. 
Three complete and nine partial remissions of the dysplastic 
lesions were observed. E7 peptide-specific CTL responses were 
detected in PBMCs from 10 patients. However, delayed type 
hypersensitivity (DTH) response was not observed in any of the 
vaccinated patients. Further, in situ RNA hybridizations showed 
no viral clearance in any of the patients, including those with 
negative Pap smear. 
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Table 2.  Clinical Studies with Therapeutic HPV Vaccines 
 
Type of 
Vaccine  Composition / Adjuvant  Via  Phase of 
Study  Patients Immune  Response  Clinical 
Response  Refs. 
HPV-16 E7
86-93 peptide conjugated 
with lipid (palmitic acid) linked to 
the non-specific PADRE helper 
peptide [65, 66] 
SC I 
12 patients (HLA-
A*0201) with refractory 
cervical or vaginal 
cancer 
E7-specific CTL 
response in 7 patients 
No clinical 
response  a 
Two HPV-16 E7 peptides (E7
12-20 
and E7
86-93) linked to the non-
specific PADRE helper peptide 
Adjuvant: IFA 
SC I-II  19 cervical cancer 
patients (HLA-A*0201) 
No E7-specific CTL 
response 
2 partial 
remissions 
b  Peptide 
vaccines 
E7
12-20 and E7
86-93 Peptides linked to 
the PADRE helper peptide bound 
to a lipid radical 
Adjuvant : IFA 
SC I 
18 patients (HLA-
A*0201) with high-
grade cervical or vulvar 
intraepithelial neoplasia 
E7-specific CTL 
response in 10 
patients 
3 complete 
remissions 
9 partial 
remissions 
c 
Fusion protein containing HPV-16 
E7 and HSP-65 of Mycobacterium 
Bovis BCG  
SC II 
22 anal HSIL patients, 
of which 14 presented 
anogenital condiloma 
Non-determined 
3 complete 
remissions 
10 partial 
remissions 
d 
Fusion protein containing HPV-16 
L2, E6 and E7 
(TA-CIN) 
IM  I  40 healthy volunteers 
E6 and E7-specific 
CTL responses in 8 
patients 
Not 
determine
d 
e 
Three doses ofTA-CIN, followed 
by one dose of TA-HPV (see below 
Viral Vector Vaccines) 
(Prime-boost trial) 
IM II  29       
Fusion protein containing HPV-16 
E6 and E7 Adjuvant: 
ISCOMATRIX
® [78] 
IM I 
8 CIN I patients 
10 CIN II patients NIC 
II 
13 CIN III patients 
Specific CTL 
responses in 5 
patients 
Delayed type 
hypersensitivity 
(DTH) 
To E6 and E7 in 18 
patients 
4 complete 
remissions 
f 
Protein 
vaccines 
Fusion protein containing an HPV-
16 E7 mutant conjugated to the 
Haemophilus influenzae protein D 
(PD-E7) 
Adjuvant : AS02B 
IM I/II 
5 CIN III patients 
2 CIN I patients 
Increase of 
preexisting cellular 
response to PD-E7 in 
5 patients 
2 
remissions 
(CIN I 
patients) 
g 
Autologous DCs loaded with 
recombinant HPV-16 or HPV-18 
E7 protein 
SC I 15 grade IV cervical 
cancer patients  
CTL responses in 4 
patients 
Antibody responses 
in 3 patients 
No h 
Dendritic 
cell 
vaccines   DCs loaded with HPV-16 E7 or 
HPV-18 
and human recombinant IL-2  
SC I 
4 cervical cancer 
patients (HPV-16+ or 
HPV-18+) refractory to 
standard treatment 
Specific antibody and 
CD4+ T lymphocytes 
in 2 patients 
Increase in E7-
specific CD8+ T cells 
in 4 patients 
No i 
ZYC101: Zycos 101 plasmid DNA 
encoding several HLA-A2 epítopes 
from HPV-16 E7 Encapsulated in 
microparticles of biodegradable 
polymer 
IM I 
12 anal dysplasia 
patients 
Increased 
responses to E7 
epitopes in10 cases 
3 partial 
remissions  j 
ZYC101 
SC / 
IM  I  15 CIN II/III patients 
11 HPV-specific 
CTL responses 
5 complete 
remissions  k  DNA 
vaccines 
Amolimogene/ZYC101a: plasmid 
DNA encoding fragments from 
HPV-16 and 18 E6 and E7 
Encapsulated in microparticles of 
biopolymer 
IM II 
127 CIN II/III patients 
(86 under treatment) 
80 Increased 
preexisting specific T 
cell responses 
37 
complete 
remissions 
l 74    The Open Virology Journal, 2009, Volume 3  Angel Cid-Arregui 
 
  Altogether, these studies demonstrated that vaccination 
with peptides even at high doses is well tolerated; yet the 
immune responses induced were insufficient to induce 
satisfactory clinical responses. One possible explanation for 
this may be that in most studies patients with advanced grade  
 
cancers were selected, whose immune function was 
somehow compromised. Nevertheless, new peptide vaccine 
strategies combining advances in engineering peptides, 
adjuvants and delivery systemsmight result in efficient anti-
tumor responses [63]. 
(Table 2) contd….. 
Type of 
Vaccine  Composition / Adjuvant  Via  Phase of 
Study  Patients Immune  Response  Clinical 
Response  Refs. 
TA-HPV vaccine: vaccinia virus 
strain Wyeth encoding a HPV 16 
and 18 E6/ E7 fusion protein 
Dermal 
scarific
ation 
I 
8 advanced cervical 
cancer patients (grades 
Ib-IIIb or recurrent) 
3 humoral responses 
against E6/E7, and 8 
anti-vaccinia 
1 HPV-specific CTL 
response 
No m 
TA-HPV  
Dermal 
scarific
ation 
I  29 cervical cancer 
patients (grade Ib o IIa) 
8 HPV-specific 
antibody responses 
4 HPV-specific CTL 
responses 
No n 
TA-HPV 
Dermal 
scarific
ation 
II  12 VIN patients 
6 CD4+ T 
lymphocyte 
responses 
10 HPV-specific 
antibody responses 
5 partial 
remissions 
1 complete 
remission 
o 
TA-HPV 
Dermal 
scarific
ation 
II  18 high grade VIN 
patients 
8 T cell proliferation 
responses 
5 INF- response 
1 humoral response 
8 partial 
remissions 
p 
MVA-E2  Intra- 
uterus 
I-II  36 CIN I, II or III 
patients 
Humoral and cellular 
responses in all cases 
34 
complete 
remissions 
q 
MVA-E2  Intra-
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Protein Vaccines 
  An advantage of protein vaccines is that they harbor 
numerous CTL epitopes and hence do not require 
determining the HLA haplotype. During the last years a 
number of cervical cancer vaccines using modified E6 and 
E7 proteins from HPV16 have been developed and tested in 
preclinical and clinical studies. One of these was a fusion 
protein named HspE7 (Stressgen, San Diego) containing the 
E7 protein of HPV16 fused to the heat shock protein (Hsp) 
65 from Mycobacterium bovis bacillus Calmette-Guerin 
(BCG), a potent activator of DC and inductor of immune 
cellular response. In a phase II clinical trial, 22 patients with 
high-grade anal intraepithelial neoplasia (AIN), positive for 
HPV16, received three doses of HspE7 vaccine (500 
g/dose, monthly) [69]. The results showed conversion to 
low-grade AIN in 13 patients within 3-6 months as well as 3 
complete remissions. Another study with HspE7 
administered to 21 patients with CIN lesions associated with 
HPV16 led to 8 remissions in two months [70]. A more 
recent clinical study with the same protein involving 133 
patients showed no difference between HspE7 and placebo 
[71]. Nevertheless, in this study the interpretation of the 
degree of dysplasia in the lesions by the different 
pathologists involved varied considerably, indicating that 
quantitative surrogate parameters such as viral load will need 
to be evaluated in further trials. In 2006, Stressgen decided 
not to go into phase III clinical trials with this vaccine 
arguing that a new formulation combining HspE7 with 
adjuvant, with which a new phase I trial was to be started 
[72], seemed to be more effective. This company changed to 
Nventa Biopharmaceuticals in 2006 andconducted a four-
cohort phase I study on healthy volunteers with HspE7 
combined with escalating doses of adjuvant containing poly-
ICLC, a toll-like receptor 3 (TLR3) agonist. The results of 
this study were announced on May 2008 [73]. In the first 
cohort (500 g HSPE7 and 50g poly-ICLC) there was 
limited E7-specific T cell response. In the second cohort 
(500 g HSPE7 and 500g poly-ICLC), three out of four 
individuals showed specific response. In the third (500 g 
HSPE7 and 1000g poly-ICLC) all four subjects responded 
with E7-specific response. However, in the fourth cohort 
(500 g HSPE7 and 2000 g poly-ICLC) only two of five 
individuals had significant increases in HPV16 E7-specific 
T-cells from baseline, while the remaining threesubjectsof 
this group maintained levels of HPV16 E7-specific T-cells 
that were already present at baseline. It was concluded that 
all dose regimens were safe and well tolerated and that doses 
of 500 g HSPE7 and 1-2 mg of Poly-ICLC were 
appropriate for phase II studies [73]. Yet the future of such 
studies remains uncertain since in May 2009 Nventa was 
acquired by another Canadian company, Akela Pharma Inc. 
[74]. 
  Another subunit protein vaccine tested in clinical trials is 
known as TA-CIN (Xenova Research Ltd., Cambridge, UK), 
a recombinant fusion protein made of HPV16 L2, E6 and E7 
produced in E. coli. A double-blind and placebo controlled 
phase I clinical study with this protein [75] included 40 
healthy women who received three escalating doses of 
protein (26, 128 and 533 g) by i.m. injection, without 
adjuvant, at 4 week intervals. Antibody responses were 
observed at all three doses. Specific E6 and E7 T cell and 
antibody responses were induced in 8 subjects vaccinated 
with the highest dose. In 2005, Xenova licensed TA-CIN to 
Cancer Research Technology (CRT) Limited, a technology 
transfer company owned by Cancer Research U.K A 
nonrandomized phase II prime-boost vaccine trial was 
conducted in 29 women with biopsy-proven genital 
intraepithelial neoplasia (27 vulvar and 2 vaginal) grade 3. 
Patients were vaccinated with three doses (maximum dose) 
of TA-CIN followed by one dose of a recombinant vaccinia 
virus encoding HPV16 and 18 E6/E7 (TA-HPV). Clinical 
responses, evaluated by serial photographs, symptoms, and 
biopsy analysis before and after vaccination, were seen in 
five women, with one complete and four partial remissions. 
Symptomatic improvement was reported in fifteen women 
[76]. Because such a prime-boost approach showed no 
significant advantage over single TA-HPV vaccination, the 
authors concluded that no further studies were planned using 
this protocol. Further analysis of the immune responses in 
the vaccinated women of both studies showed that 
vaccination induced L2-specific neutralizing antibodies. 
However, patients responded less effectively to vaccination 
than healthy volunteers for induction of HPV16 L2-specific 
antibodies, suggesting tolerance to HPV antigens in patients 
due to some underlying immune deficit [77]. 
  A recombinant fusion protein containing E6 and E7 of 
HPV16, expressed in E. coli, was also tested in a phase I 
clinical trial with 42 healthy volunteers who received three 
i.m. doses of E6E7 protein in combination with the adjuvant 
Iscomatrix
 [78]. All vaccinated subjects had E6E7 antibody 
responses and in 80% T cell responses were demonstrated 
[79]. Later on, 31 CIN patients were enrolled into a 
randomized blinded placebo controlled dose ranging phase I 
trial. Antibody, DTH, and CD8 T cell responses to E6 and 
E7 proteins were significantly greater in the immunized 
subjects than in placebo recipients [80]. A reduction of viral 
load was detected in some patients. Follow-up studies with 
this protein have not been reported to date 
  One subunit vaccine also designed to enhance the cellular 
immune response to E7 contained a fusion of an HPV16 E7 
mutant with the first amino acids of the Haemophilus 
influenzae protein D (PD-E7) in AS02B adjuvant (Adjuvant 
System 2B, GlaxoSmithKline), which consists of an 
emulsion of monophosphoryl lipid A and QS21, a saponine 
extract from the south American tree Quillaja saponaria 
Molina. In a first clinical study, five patients with HPV16 
positive, histologically demonstrated severe cervical 
dysplasia (CIN III) received three doses of the vaccine four 
weeks apart (within two months) before conization (removal 
of the lesions) was performed. Histological analysis of the 
biopsies showed CD4+ and CD8+ T cell infiltration and a 
limited degree of regression [81]. In a second phase I/II 
clinical trial seven patients, five with CIN III and two with 
CIN I, received three i.m. injections of PD-E7/ AS02B at 2-
week intervals. As control, three CIN I patients received 
placebo. Conization and histological analysis was performed 
8 weeks after vaccination. All vaccinated patients had 
significant E7 and PD specific IgG antibodies. Preexisting 
CD4+ and CD8+ responses to PD-E7 were detected in one 
and five patients, respectively. Five vaccinated patients 
showed significantly increased IFN- CD8+ T cell responses 
to E7. However, clinical response was only observed in the 
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concluded that a clinical study with a larger number of 
patients should be carried out to further analyze the efficacy 
of the PD-E7/ AS02B vaccine. Nevertheless, no new studies 
with this vaccine have been reported to date. 
Dendritic Cell Vaccines 
  DCs are a heterogeneous group of multifunctional 
antigen presenting cells (APCs) [83]. DCs present self 
peptide-MHC complexes to lymphoid cells in the thymus to 
induce T cell-tolerance. They also present non-self peptide-
MHC complexes to naïve and memory T cells to induce T 
cell activation from the resting or naive state into distinct 
classes of effector cells due to their ability to deliver co-
stimulatory signals [84]. Upon activation with different 
stimuli DCs achieve maturation thereby expressing high 
levels of several molecules at the cell surface: early 
activation markers such as CD83, MHC class I and II, as 
well as accessory molecules like CD40, CD80, CD86. 
  DCs are currently being studied as adjuvants for vaccines 
or as a direct therapy to induce immunity against cancer in 
two different approaches [83, 85]: 1) DCs can be easily 
isolated from peripheral blood, expanded ex vivo, loaded 
with tumor antigens and injected back into the patient as 
activated autologous APCs, thus taking advantage of their 
ability to migrate to lymphoid organs and induce T cell and 
NK responses; and 2) tumor antigens are targeted directly to 
DCs using monoclonal anti-DC antibodies. An important 
limitation is that DCs do not proliferate and after a certain 
time course they undergo apoptosis being replaced by a new 
pool of cells. Thus, their short half life limits their ability to 
stimulate effective, long lasting antigen-specific T cell 
responses. 
  A DC based vaccine was applied to a case of HPV18+ 
cervical adenocarcinoma complicated with pulmonary 
metastases [86]. The patient received 14 consecutive doses 
(3-5 x 10
6 cells/dose injected s.c.) of autologous DCs loaded 
with HPV18 E7 protein. In addition, 72 hours after the 1
st, 
2
nd and 4
th doses the patient received a dose of autologous T 
cells stimulated in vitro with E7-loaded DCs. Serial 
computer tomography scans and histological analysis of 
tumor biopsies carried out 10 months after the initial 
vaccination showed metastasis growth arrest with fibrosis 
and macrophage infiltration of tumors. However, metastasis 
growth reactivated at month 20 and the patient died three 
months later. 
  Another DC based vaccine was tested in a phase I 
clinical trial with 15 stage IV cervical cancer patients using 
monocyte-derived autologous DCs loaded with E7 protein 
from HPV16 or HPV18 [87]. The vaccine was well tolerated 
and no side effects were observed. A specific antibody 
response was seen in 3 subjects and T cell responses were 
detected by IFN- and ELISPOT assays in 4 patients. 
However, no clinical responses were observed. Strong 
reduction or loss of HLA expression was detected in tumor 
biopsies of three out of four patients analyzed. The authors 
concluded that in future studies patients with confirmed 
tumor HLA expression should be selected and that boosting 
of immune responses by adjuvants should be introduced. In a 
more recent clinical study, four patients harboring 
recurrent/metastatic cervical cancer refractory to 
conventional treatment received autologous monocyte-
derived DCs pulsed with recombinant HPV16 E7 or HPV18 
E7 protein [88]. Three out of four patients were significantly 
immunocompromised before starting vaccination, as 
detected by DTH with various antigens. Vaccinations were 
followed by s.c. administration twice daily of low doses of 
human recombinant IL-2 (1 x 10
6 IU/m
2) from day 3 to day 
7. Specific humoral and cellular CD4+ T cell responses to 
E7 were detected in 2 patients by ELISA and IFN- 
ELISPOT assays. Increased numbers of E7-specific IFN- 
secreting CD8+ T cells were detected in all patients after 
vaccination. In addition, a positive DTH response to the 
intradermal injection of HPV E7 protein and/or irradiated 
autologous tumor cells was detected in two patients after six 
vaccinations. Again, no objective clinical responses were 
observed, although both patients with positive DTH to the 
vaccine had a slower tumor progression (13 months survival 
from the beginning of therapy) in comparison to DTH 
unresponsive patients (5 months). It was concluded that 
treatment-induced immunosuppression in late stage cervical 
cancer patients may represent a severe limitation to the 
efficacy of DC vaccination. 
DNA Vaccines 
  Plasmid DNA based vaccines have been shown to induce 
CTL and antibody responses to HPV antigens [89, 90]. A 
DNA vaccine originally named ZYC101 (Zycos Inc.) 
consists of plasmid DNA encapsulated in biodegradable 
poly[lactide-co-glicolide] polymer microparticles, which 
should favor cell entry. The plasmid encodes a sequence of 
HPV-16 E7 containing several overlapping HLA-A2-
restricted epitopes fused to a secretory signal derived from 
the HLA-DRA*0101 locus [91, 92]. A phase I dose 
escalation clinical trial included 12 patients with anal 
dysplasia associated to HPV16 infection, all with HLA-A2 
haplotype. The patients were vaccinated with four i.m. 
injections of 50-400 g of ZYC101 at 3-week intervals [91]. 
The vaccine was well tolerated at all doses tested. In 10 
subjects there was increased immune response to the peptide 
epitopes encoded by the plasmid as demonstrated by direct 
ELISPOT, which continued 6 months after the initiation of 
therapy. Partial histological responses were observed in three 
patients, one receiving the 200 and two the 400 g dose. In a 
later phase I study 15 HLA-A2 women with HPV16 (+) CIN 
II or III received three doses (i.m. and s.c.) of the same 
vaccine at 3-week intervals, followed 4 weeks later by 
surgical excision [92]. E7 peptide-specific T cell responses 
were demonstrated in 11 patients by an IFN- ELISA assay. 
In addition, complete regression of cervical lesions was 
observed in 5 patients, of whom 4 showed anti-HPV16 E2 
IgA responses in cervical smears. Such immune reactivity to 
an HPV antigen not included in the vaccine was interpreted 
as lysis of infected cells caused by the T cell responses 
induced by vaccination. 
  A second generation of this vaccine, initially named 
ZYC101a, contains plasmid DNA encoding fragments 
derived from the E6 and E7 proteins of HPV16 and !8 
formulated within polymer microparticles [93]. It was tested 
in a multicenter, double-blind, randomized, placebo-
controlled trial which included 161 patients with biopsy-
confirmed CIN II/III lesions. The patients were randomized 
to 3 i.m. doses of either placebo or ZYC101a (100 or 200 
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months after the first injection. The primary endpoint for this 
study was histologically confirmed resolution of the CIN. A 
central pathology review selected 127 patients as evaluable 
for efficacy. Mild to moderate adverse effects were observed 
at the injection site. A higher proportion of ZYC101a 
vaccinated patients resolved the CIN lesions as compared to 
the placebo-vaccinated group (43% vs 27%), but this 
difference was not statistically significant (P =0.12). 
Nevertheless, in a prospectively restricted group of women 
younger than 25 years (n = 43), resolution was significantly 
higher in the combined ZYC101a groups compared to 
placebo (70% vs 23%; P =0.007). Since Zycos Inc. was 
acquired by MGI Pharma in the year 2005 ZYC101a was 
renamed Amolimogene. This company sponsors currently a 
phase II clinical trial (multi-center, double-blinded, 
randomized, placebo-controlled) with 288 CIN II/III patients 
younger than 25 years [72, 94], whose completion is 
expected this year (ClinicalTrials.gov Identifier: 
NCT00264732) [95]. 
Viral Vector Vaccines 
  A number of RNA and DNA viruses have been 
engineered as recombinant viral vectors [96]. It is believed 
that future success in the field of gene therapy and cancer 
vaccines will be closely linked to the development of new 
generations of viral vectors [97]. Important advantages of 
viral vectors are their ability to infect a variety of cell types 
including DCs and their superior efficiency in transducing 
and expressing heterologous genes. Upon administration, the 
vector infects host cells and drives expression of tumor 
antigen, which is processed and presented as a viral antigen 
generating MHC class I-restricted CTL as well as humoral 
responses. The main limitations of viral vectors are related to 
safety concerns, high production costs and their stability, 
which requires frozen conservation. 
  Several vaccines based on vaccinia virus vectors 
designed to induce long-lasting CTL responses against HPV 
E2 E6 and E7 antigens are being tested in clinical trials 
(Table 2). This virus is highly immunogenic and causes lysis 
of the infected cells, which ensures uptake of HPV antigens 
by APCs. In addition, lysis minimizes the risk of insertional 
mutagenesis or other effects due to the viral proteins. The 
first HPV vaccine of this type was the so called TA-HPV, 
which carries E6/E7 genes of HPV16 and HPV18 inserted 
into the genome of the strain Wyeth of vaccinia virus. In 
both pairs of genes the stop codon of E6 was removed to 
create fusion E6-E7 genes. In addition a mutation was 
introduced in the E7 genes to inactivate the site of interaction 
with pRb. This vaccine was first tested in an open label 
phase I/II trial in eight patients with late stage cervical 
cancer, who received a single dose of TA-HPV [98]. All 
patients reacted with anti-vaccinia antibodies and three 
subjects developed an HPV-specific antibody response. One 
patient developed an HPV-specific CTL response. No 
clinical response was observed. A second phase I trial 
included 29 patients with clinical stage Ib or IIa cervical 
cancer. The patients were vaccinated with TA-HPV twice 
(2.5x10
5 pfu by scarification) 4 weeks apart, starting 2 weeks 
before radical hysterectomy was carried out [99]. An HPV-
specific CTL response was found in 4 patients, while 8 
patients developed HPV-specific antibody responses. Again, 
no clinical benefit was observed. Later on, the TA-HPV 
vaccine was tested in a phase II study in 12 patients (aged 
42-54 years) with high-grade vulvar or vaginal intraepithelial 
neoplasia of up to 15 years duration [100]. An increased 
HPV-specific T-cell response was demonstrated in 6 patients 
by IFN- ELISPOT using pooled 22-mer peptides spanning 
HPV-16 E6 and E7. Clinically, a 50% reduction in lesion 
diameter in 5 patients over 24 weeks and a complete 
remission were observed. In a parallel phase II study, 18 
women with HPV16 (+) high-grade vulvar intraepithelial 
neoplasia were vaccinated with a single dose of TA-HPV 
and their clinical and analytical status was monitored over a 
follow-up period of 6 months [101]. Overall, 13 patients 
showed an increased HPV 16-specific immune response. Of 
these, 8 women experienced a reduction in lesion diameter of 
at least 50%. Viral load, measured before and after 
vaccination by real time PCR, was reduced or cleared in six 
of eight clinical responders but also in 6 out of 10 non-
responders. Interestingly, clinical responders had 
significantly higher levels of lesion-associated CD4(+), 
CD8(+), and CD1a(+) T cells before vaccination, as 
compared with non-responders. The authors concluded that 
the degree of local T cell infiltration might be a critical factor 
in the development of effective responses to vaccine therapy 
in HPV-associated neoplasia. None of these studies were 
placebo-controlled. In another study by the same authors, 10 
patients with HPV 16-positive high grade VIN, previously 
primed with TA-HPV, received three doses of TA-CIN 
[101]. HPV 16-specific T-cell and/or serological responses 
were demonstrated in 9 patients, three of whom showed 
lesion shrinkage or symptom relief. However, no direct 
correlation between clinical and immunological responses 
was seen. 
  Another vaccinia-HPV vaccine used a Modified vaccinia 
Ankara (MVA) virus, a highly attenuated replication-
deficient vaccinia strain, expressing the HPV16 E2 protein 
(MVA-E2). In a phase I/II trial 78 patients with CIN I, II or 
III were enrolled, of which 36 were inoculated in the uterus 
with six doses of MVA-E2 (10
7  virus particles/dose) at 
weekly intervals, while the rest were treated with 
cryosurgery [102]. The evolution of the lesions after 
vaccination was followed weekly by colposcopy and 
cytology analysis. In the vaccinated group, 34 out of 36 
patients were reported to show complete remission, while 2 
subjects showed partial remission (from CIN III to CIN I). 
Antibody responses to the MVA-E2, as well as specific 
cytotoxic responses against cancer cells bearing HPV DNA 
were detected in all patients in this group. The viral DNA 
was cleared in 50% of these patients. In the cryosurgery 
group the CIN lesions were removed, but the patients did not 
develop cytotoxic activity against cancer cells bearing HPV 
DNA. In later study with the MVA-E2 vaccine 34 patients 
with high-grade CIN were vaccinated following the same 
protocol [103]. Histological analysis showed complete 
remission of the lesions in 20 patients. Again, all vaccinated 
women developed HPV-specific antibody and cytotoxic 
responses. A control group treated surgically to eliminate the 
lesions did not develop cytotoxic responses against HPV. A 
more recent study with the MVA-E2 vaccine in men with 
intraurethral flat condiloma showed similar efficacy of the 
vaccine in clearing the lesions [104]. None of these reports 
informed on the immune status of the patients and whether 
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vaccination. In addition, the evolution of the lesions and 
their size was determined by colposcopy, which may lead to 
error. No placebo control was included in these two studies. 
  The third HPV-viral vector vaccine under clinical study 
is named MVA-HPV-IL2 or TG4001/R3484 (Transgene S 
A, Strasbourg) [105]. It is based on vaccinia MVA that was 
engineered to express HPV E6 and E7 proteins containing 
deletions in their domains interacting with p53 and pRb, 
respectively, as well as IL-2 to enhance innate and acquired 
cellular immune responses to the HPV antigens. This 
company disclosed of three Phase I clinical studies with TG 
4001/R3484 aimed to determine the safety of the product, 
which was injected i.m., and to define the dose to be used in 
further clinical trials. Subsequently, a 6-week Phase II trial 
enrolled 31 patients with HPV16-related CIN II/III, of whom 
29 were evaluable for vaccine efficacy. The patients were 
randomized into two groups, which received two different 
doses (5x10
5 pfu and 5x10
7 pfu) of MVA-HPV-IL2, 
followed by conization six weeks after vaccination. There 
was some reduction in the lesion size or grade in 5 out of 19 
patients vaccinated with the higher dose, as determined by 
histological analysis, while no responses were observed in 
the 12 patients inoculated with the lower dose. A second 
phase II trial was conducted to evaluate the efficacy of 
MVA-HPV-IL2 at the highest dose (5x10
7 pfu) in a 6-month 
follow up period from the first vaccination [106]. The 
studyenrolled 21 patients aged 25 to 44 years with HPV16 
(+) CIN II/III and was carried out in nine health centres in 
France. All patients received three s.c. injections of MVA-
HPV-IL2 at the dose of 5x10
7 pfu. Cytology and virus 
detection analyses were performed. Transgene S.A. 
announced that six months after vaccination 10 women 
(47,6%) had no more CIN II/III and that HPV16 E6 and E7 
mRNA could not be detected in any of the responders. 
However, the spontaneous regression rate of CIN lesions in 
that age group has been estimated to be up to 46% [107]. 
This company entered last year into a cooperation agreement 
with Roche Holding A G and announced a placebo-
controlled Phase III trial programme enrolling an estimated 
500 HPV16 (+) CIN II/III patients in Europe and the U.S. 
[108]. 
  In addition to vaccinia, a number of other virus vectors 
harboring HPV antigens have been tested in preclinical 
studies with laboratory animals, such as three genera of the 
Alphavirus family, namely Sindbis virus (SV), Semliki 
Forest virus (SFV) and the Venezuelan equine encephalitis 
virus (VEEV), as well as recombinant adenovirus (rAd). A 
SV vector vaccine was constructed encoding a fusion of 
HPV16 E7 and the tegument protein VP22 of herpes simplex 
virus type 1. VP22 should facilitate intercellular transport of 
E7, thus enhancing its presentation to the immune system 
[109]. This vaccine induced in mice CD8+ T cell responses 
that conferred protection against tumor cells expressing E7. 
A SFV recombinant virus used to express a fusion of the 
HPV16 E6 and E7 proteins elicited CTL responses and 
antitumor effects [110]. Vaccination with VEEV-based 
replicon particles expressing HPV16 E7 induced class I-
restricted CD8+ T cell responses, leading to regression of 
established tumors in 67% of tumor bearing mice and 
prevented tumor development in all vaccinated mice [111]. 
Further, the same vector encoding a fusion of the HPV16 E6 
and E7 proteins protected 100% of mice from tumor 
development after challenge with E7-expressiong TC-1 
tumor cells [112]. An experimental vaccine based on rAd 
encoded a fusion protein composed of the hepatitis B surface 
antigen (HBsAg) and a non-transforming truncated mutant 
of the HPV16 E7 protein devoid of its pRb-binding domain 
[113]. Mice vaccinated with low doses of this vaccine 
developed E7-specific CTL and antibody responses and were 
protected against challenge with isogenic tumor cells 
harboring E7. To date, no clinical trials have been reported 
with any of these recombinant viruses. 
  Despite the great potential of replication-defective 
viruses as vectors, they harbor risks that limit their clinical 
use, such as toxicity due to unwanted viral gene expression, 
immune responses towards viral antigens, insertional 
mutagenesis or potential recombination and reversion to a 
replication-competent form. In addition, the development of 
immune responses to the vector or the existence of previous 
immunity against viral antigens may pose some limitations. 
For instance, a large proportion of the population over the 
age of 35 years was vaccinated with vaccinia virus during 
the campaigns to eradicate smallpox. Therefore, under such 
circumstances, immunization with vaccinia vectors may 
induce strong memory responses that could hinder response 
to the HPV antigens. A possible way to overcome this 
problem could be the use of protocols combining 
heterologous prime/boost immunizations. Thus, for instance, 
it has been shown that prime/boost immunization with TA-
CIN and TA-HPV enhanced cytotoxic responses in mice 
[114]. 
Ongoing Preclinical Studies 
  An increasing number of experimental vaccines are being 
tested in laboratory animals, mostly in mice. Currently, 
strategies focus preferentially on the use of larger peptides or 
fusion proteins and the plasmids encoding them with the aim 
of facilitating presentation of a larger number of CTL and T 
helper viral epitopes. In a study with mice, immunization 
with a 35mer peptide derived from HPV16 E7, which 
contained various CTL and T helper epitopes, elicited a 
stronger CTL response as compared with immunization 
using a smaller peptide carrying a single CTL epitope [115]. 
In addition, studies on rabbits infected with the CRPV show 
that immunization with large peptides harboring CTL 
epitopes can induce clearance of latent infection and reduce 
growth of established papillomas in a significant number of 
animals [116]. These results support the notion that long 
peptides are more effective vaccines, probably because they 
carry several epitopes and because their presentation is more 
effective, as it requires processing by antigen presenting 
cells rather than simple binding to MHC molecules. 
  In the field of dendritic cell vaccines, efforts are being 
made to improve their capacity to induce CTL responses by 
strategies that include loading DCs with HPV peptides 
combined with siRNA against the transcripts of the two pro-
apoptotic genes Bak and Bax to lengthen survival of DCs 
and thus amplify their immunogenic effects [117]. Another 
strategy used was transfection of DCs with a gene encoding 
a mutant shuffled E7 protein [118]. 
  Preclinical studies with DNA vaccines comprise a wide 
range of strategies directed to improve antigen expression 
and favor presentation by MHC class I. The first has been HPV Vaccines  The Open Virology Journal, 2009, Volume 3    79 
achieved through optimization of the codon usage of HPV 
genes replacing the viral codon sequences by synthetic genes 
containing codons frequently used in highly expressed 
human genes [24, 89]. The second objective has been 
approached in various ways such as: (i) targeting HPV 
antigens to centrosomes to favor antigen presentation 
through MHC class I molecules [119], (ii) fusion of HPV 
antigens to ubiquitin to direct them to the degradation 
pathway [111, 120], (iii) fusion to calreticulin to facilitate 
interaction with MHC class I molecules [121], (iv) a triple 
fusion protein comprising an HPV16 E6 epitope, the 2-
microglobulin and a heavy chain of MHC class I to avoid 
processing of the antigen and facilitate a stable antigen 
presentation [122], (v) fusion to the HSV VP22 protein to 
enable intercellular transference of the HPV antigen and 
hence a broader presentation [123]. 
CONCLUSIONS AND PERSPECTIVES 
  Clinical studies indicate that prophylactic vaccines have 
no therapeutic effects and therefore cannot be applied to 
women with persistent HPV infection, who are at risk of 
developing cervical cancer. Indeed, prophylactic vaccines do 
not provide protection against progression to CIN induced by 
HPV present at the time of vaccination [61, 124]. Therefore, 
millions of women already infected by HR-HPV are in need 
of therapies that help their immune system to clear the 
infection. The significant relapse rate associated with the 
conventional therapy of CIN and the high mortality 
associated with cervical cancer (30-40%), together with the 
possibility that a successful immunotherapy strategy against 
HPV-associated tumors might be extrapolated to non-viral 
cancers, altogether warrant further attempts to develop 
therapeutic vaccines targeting tumor-HPV antigens. This is 
reflected in the large number of strategies and studies that 
have reached clinical trials phase I or II. Table 2 summarizes 
results of 19 studies, in which a total of 490 patients were 
enrolled. Leaving out the trials with viral vectors, a total of 
14 partial and 54 complete remissions were reported out of 
309 patients. Of these, 42 were obtained with DNA, 9 with 
protein and 3 with peptide vaccines. Among trials using 
Vaccinia virus as vector, the E6/E7/IL-2 vaccine gave 15 
partial remissions out of 53 patients, but apparently the most 
successful was the BPV (bovine papillomavirus)-E2 vaccine 
with 11 partial and 54 complete remissions out of 70 patients 
studied. However, the lack of placebo controls restricts the 
significance of the later studies, which have also been 
questioned because E2 from BPV instead of HPV was used 
and because the vaccine was applied directly at the tumor 
site (intrauteral or intraurethral) [63]. An additional 
drawback of the vaccines based on recombinant vaccinia 
virus is that most people over age 35 were vaccinated with 
vaccinia virus against smallpox in childhood and thus may 
have neutralizing antibodies that hamper infection by the 
recombinant virus. 
  Despite the large number of clinical studies testing 
therapeutic HPV vaccines, no clear candidate vaccine for 
further clinical development has been identified to date. This 
may be explained by the intrinsic complexity of developing a 
product capable of stimulating the immune system to 
eradicate HPV-transformed cells, but also by several factors 
associated with the design and interpretation of clinical 
trials. Among these are inadequate selection and 
characterization of patients, small number of patients 
enrolled, absence of placebo controls and reluctance to 
perform double-blind studies. In the few studies in which 
patients with advanced cervical cancer were enrolled, the 
results showed limited efficacy, although the same vaccine 
had shown previously its ability to eradicate established 
HPV-bearing tumors in mice. The lack of correlation 
between mouse and human outcome is likely due to the more 
complex situation in natural infection, which progress 
through pre-neoplastic stages (Fig. 4) that may persist one to 
two decades before invasive cancer develops. This gives the 
virus time enough to adapt to the various barriers posed by 
the host’s immune system and persist awaiting the occasion 
when tumor surveillance is compromised and the 
mechanisms of cellular immunity are down (Fig. 4). 
Therefore, future clinical trials to determine the efficacy of 
therapeutic vaccines should preferably enroll patients with 
precancerous lesions or early stage cervical cancer rather 
than patients in advanced stages of the disease. Ideally, 
factors like for instance MHC class I expression and antigen 
presenting capability by tumor cells, and the levels of 
MICA/MICB shedding from the tumor, should be carefully 
assessed to better select and evaluate the patients with 
respect to their suitability for immunotherapy trials. 
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ABBREVIATIONS 
AIN =  Anal intraepithelial neoplasia 
APC =  Antigen presenting cells 
BCG =  Mycobacterium  bovis bacillus Calmette-Guerin 
CIN =  Cervical intraepithelial neoplasia (grades I, II   
   or  III) 
CRPV =  Cottontail rabbit papillomavirus 
CxCa =  Carcinoma of the uterine cervix, or cervical   
     cancer uteri 
DC =  Dendritic cell 
DTH =  Delayed type hypersensitivity 
GMP =  Good manufacturing production 
HBsAg =  Hepatitis B surface antigen 
HPV =  Human Papillomavirus 
HR-HPV =  High-risk HPV 
Hsp =  Heat shock protein 
IFA,   Incomplete  Freund’s  adjuvant 
IRF =  Interferon regulatory factor 
LC =  Langerhans Cells 
MICA =  Major histocompatibility complex class I-   
     related chain A 
MVA =  Modified vaccinia Ankara 
NK =  Natural killer 80    The Open Virology Journal, 2009, Volume 3  Angel Cid-Arregui 
PADRE = Pan:HLA DR peptide 
PBMC =  Peripheral blood mononuclear cells 
pRb =  Retinoblastoma protein 
rAd =  Recombinant adenovirus 
SFV =  Semliki Forest virus 
SV =  SINDBIS virus 
TAP =  transporter associated with antigen processing 
TLR =  Toll-like receptor 
TSA =  Tumor-specific antigen 
VEEV =  Venezuelan equine encephalitis virus 
VIN =  Vulvar intraepithelial neoplasia 
VLP =  Virus like particle 
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